清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

医学 拉帕蒂尼 乳腺癌 内科学 曲妥珠单抗 肿瘤科 三苯氧胺 来曲唑 人口 活检 阶段(地层学) 激素受体 病态的 胃肠病学 癌症 古生物学 环境卫生 生物
作者
Antonio Llombart-Cussac,Javier Cortés,Laia Paré,Patricia Galván,Begoña Bermejo,Noelia Martínez,María Vidal,Sònia Pernas,Rafael López,Montserrat Muñoz,Paolo Nuciforo,Serafín Morales Murillo,Mafalda Oliveira,Lorena de la Peña,Alexandra Peláez,Aleix Prat
出处
期刊:Lancet Oncology [Elsevier]
卷期号:18 (4): 545-554 被引量:252
标识
DOI:10.1016/s1470-2045(17)30021-9
摘要

Background HER2-positive breast cancer consists of four intrinsic molecular subtypes—luminal A, luminal B, HER2-enriched, and basal-like—and a normal-like subtype, with the HER2-enriched subtype having the highest activation of the EGFR–HER2 pathway. We aimed to test the hypothesis that patients with the HER2-enriched subtype benefit the most from dual HER2 blockade. Methods PAMELA is an open-label, single-group, phase 2 trial done in 19 hospitals in Spain. We recruited female patients aged at least 18 years with previously untreated, centrally confirmed HER2-positive, stage I–IIIA invasive breast cancer regardless of hormone receptor status. Patients were given lapatinib (1000 mg per day orally) and trastuzumab (loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks intravenously) for 18 weeks; hormone receptor-positive patients were additionally given letrozole (2·5 mg per day orally; if menopausal) or tamoxifen (20 mg per day orally; if premenopausal). Surgery was done 1–3 weeks after the last dose of study treatment. Intrinsic molecular subtypes of tumour biopsy samples taken at baseline (day 0) and day 14 were determined with the PAM50 predictor. The primary outcome was the ability of the HER2-enriched subtype to predict pathological complete response at the time of surgery. The primary outcome was assessed in the evaluable population (ie, all patients who had initial tumour biopsy samples available and who underwent definitive surgery) and safety was assessed in all patients who received at least one part of study treatment. This study is registered with ClinicalTrials.gov, number NCT01973660, and is completed. Findings Between Oct 28, 2013, and Nov 26, 2015, we recruited 151 patients, of whom 14 (9%) discontinued treatment and 137 (91%) completed treatment as planned. At baseline, most patients had the HER2-enriched subtype (101 [67%]), followed by luminal A (22 [15%]), luminal B (16 [11%]), basal-like (nine [6%]), and normal-like (three [2%]) subtypes. At the time of surgery, 46 (30%, 95% CI 23–39) of 151 patients had pathological complete response in the breast. 41 (41%, 31–51) of 101 patients with the HER2-enriched subtype and five (10%, 4–23) of 50 patients with non-HER2-enriched subtypes achieved pathological complete response at the time of surgery (odds ratio 6·2, 95% CI 2·3–16·8; p=0·0004). Interpretation The HER2-enriched subtype can identify patients with HER2-positive breast cancer who are likely to benefit from dual HER2 blockade therapies. Funding GlaxoSmithKline, Susan Komen Foundation, CERCA Programme—Generalitat de Catalunya, Banco Bilbao Vizcaya Argentaria Foundation, Pas a Pas, and the Breast Cancer Research Foundation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
leng完成签到 ,获得积分10
5秒前
dragonhmw完成签到 ,获得积分10
7秒前
烟花应助依居采纳,获得10
14秒前
玉一一完成签到 ,获得积分10
18秒前
哈拉斯完成签到,获得积分10
19秒前
21秒前
依居发布了新的文献求助10
27秒前
蓝胖胖蓝完成签到,获得积分10
33秒前
53秒前
稀松完成签到,获得积分10
54秒前
57秒前
陌子完成签到 ,获得积分10
1分钟前
zjq完成签到 ,获得积分10
1分钟前
1分钟前
飞云完成签到 ,获得积分10
1分钟前
铁妹儿完成签到 ,获得积分10
1分钟前
SHD完成签到 ,获得积分10
1分钟前
煜琪完成签到 ,获得积分10
2分钟前
高贵逍遥完成签到 ,获得积分10
2分钟前
wyh295352318完成签到 ,获得积分10
2分钟前
jie完成签到 ,获得积分10
2分钟前
さくま完成签到,获得积分10
2分钟前
啥时候能早睡完成签到 ,获得积分10
2分钟前
dbdxyty完成签到,获得积分10
2分钟前
沉香如兰完成签到,获得积分10
2分钟前
幸福安康完成签到 ,获得积分10
3分钟前
mark33442完成签到,获得积分10
3分钟前
qq完成签到 ,获得积分10
3分钟前
潇潇雨歇完成签到,获得积分10
3分钟前
3分钟前
3分钟前
洁净的盼易完成签到 ,获得积分10
3分钟前
枫林摇曳完成签到 ,获得积分10
3分钟前
葫芦芦芦完成签到 ,获得积分10
3分钟前
魔幻的慕梅完成签到 ,获得积分10
3分钟前
成就的笑南完成签到 ,获得积分10
3分钟前
wujiwuhui完成签到 ,获得积分10
4分钟前
温婉的人雄完成签到,获得积分10
4分钟前
xzy998应助依居采纳,获得10
4分钟前
zz完成签到 ,获得积分10
4分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052630
求助须知:如何正确求助?哪些是违规求助? 2709863
关于积分的说明 7418232
捐赠科研通 2354395
什么是DOI,文献DOI怎么找? 1246007
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921